Mangrove Partners Larimar Therapeutics, Inc. Transaction History
Mangrove Partners
- $637 Million
- Q1 2025
A detailed history of Mangrove Partners transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Mangrove Partners holds 770,233 shares of LRMR stock, worth $2.85 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
770,233
Previous 770,233
-0.0%
Holding current value
$2.85 Million
Previous $2.94 Million
43.71%
% of portfolio
0.26%
Previous 0.46%
Shares
8 transactions
Others Institutions Holding LRMR
# of Institutions
121Shares Held
64.9MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$78.6 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$22.4 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$20.6 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$18.2 Million7.71% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$12.6 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $160M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...